Davis Polk advised Affimed N.V. on its $26.5 million public offering of 13,225,000 of its common shares. Included in the shares are 1,725,000 shares sold by Affimed pursuant to the underwriters’ exercise in full of their option to purchase additional shares.
The common shares are listed on the NASDAQ Global Market under the symbol “AFMD.”
Based in Heidelberg, Germany, Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells.
The Davis Polk corporate team included partner Sophia Hudson (Picture) and associates Dan Gibbons and Pedro J. Bermeo. The tax team included partner Michael Mollerus and associate Erin Harvey. Associate Colleen Blanco provided 1940 Act advice.
Involved fees earner: Sophia Hudson – Davis Polk & Wardwell; Dan Gibbons – Davis Polk & Wardwell; Pedro Bermeo – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Erin Harvey – Davis Polk & Wardwell; Colleen Blanco – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;
Clients: Affimed Therapeutics;